- Company
- Shionogi's stock price is soaring
- by Eo, Yun-Ho Nov 25, 2021 05:56am
- Shares of Japan's Shionogi Pharmaceutical, which is developing a treatment for COVID-19 with Ildong Pharmaceutical, are on the rise day after day. According to related industries, Shionogi's stock price has steadily risen since August, breaking this year's highest price. As of the 24th, Shionogi Pharmaceutical's stock price is trading at a
- Company
- Opdivo combo in review for esophageal cancer indication
- by Eo, Yun-Ho Nov 24, 2021 05:53am
- The cancer immunotherapy ‘Opdivo’ is attempting to add another esophageal cancer indication as a combination therapy in Korea. According to industry sources, the Ministry of Food and Drug Safety is reviewing expanding the indication for Ono·BMS’s PD-1 inhibitor Opdivo (nivolumab) in combination with Yervoy (ipilimumab) or chemotherapy
- Company
- Bavencio cost support provided in non-reimbursed areas
- by Eo, Yun-Ho Nov 23, 2021 05:54am
- Pharmaceutical expense support for the cancer immunotherapy drug ‘Bavencio’ in non-reimbursed areas has begun. According to industry sources, Merck and Pfizer have started a patient support program to refund part of the expenses patients spend on Bavencio (avelumab) as first-line monotherapy for metastatic Merkel cell carcinoma and as f
- Company
- Myungin signed an exclusive license agreement for Parkinson
- by Nov 23, 2021 05:54am
- Myungin announced on the 22nd that it has signed a license and investment contract with Israeli pharmaceutical company Pharma Two B (P2B) for commercialization of Parkinson's disease treatment in Korea. P2B001, which is being developed by P2B, is a new combination of low-dose sustained-release drug Rasagilin and sustained-release drug Pram
- Company
- Maven Clad can be prescribed in Big 5
- by Eo, Yun-Ho Nov 23, 2021 05:54am
- Maven Clad, a new drug for multiple sclerosis, has completed its entry into the Big 5 Advanced General Hospitals. According to related industries, Merck's highly active multiple sclerosis treatment Maven Clad (Cladribine) has currently passed DC of medical institutions such as Samsung Medical Center, Seoul National University Hospital, Se
- Company
- Prolonged delay in GSK vaccine supply may cost ₩30 bil
- by Nov 22, 2021 05:52am
- The discontinuation in the supply of many GSK vaccines is causing greater ripples. With the rising possibility that the situation may be prolonged, concerns continue over the sales gap, and procurement of substitutes is rising. GSK had announced the supply setbacks of 9 of its vaccines to primary clinics and hospitals on the 25th. The va
- Company
- Yuhan has secured 260 billion won in technology fee in 3 yrs
- by Chon, Seung-Hyun Nov 22, 2021 05:52am
- Yuhan Corporation is creating a case of securing additional technology fees by advancing to the development stage even after exporting new drug technologies. It has secured a total of 260 billion won in new drug technology exports over the past 3 years. It has secured more money with additional technology fees than the down payment secured by ex
- Company
- Viatris Korea will participate in the IMPACT WEEK
- by Eo, Yun-Ho Nov 22, 2021 05:52am
- Vitris Korea celebrated its first anniversary. On the 16th, Viatris announced that it will participate in the IMPACT WEEK designated by the world to mark the first anniversary of its launch, reflect on the past year, and carry out activities to commemorate the first anniversary with executives and employees. During Impact Week, Viartris wi
- Company
- All-round prostate cancer treatment Xtandi with solid growth
- by Nov 18, 2021 05:55am
- Xtandi (enzalutamide)' rose to the ranks and became a blockbuster drug last year after continuously extending its indication in prostate cancer, a field that lacked treatment options. Although the drug was approved later than its competitor, through its continuous expansion effort, Xtandi became the only single-agent drug that is approved fo
- Company
- Domestic approval of Tabrecta is imminent
- by Eo, Yun-Ho Nov 18, 2021 05:54am
- According to related industries, the MFDS is conducting a final review for marketing approval of Tabrecta (Capmatinib) of Novartis Korea. Approval is possible within this year. MET mutations account for about 3% to 4% of metastatic non-small cell lung cancer, and as there have been no treatments, interest in these new drugs is increasing.
